{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:15Z","timestamp":1785484695345,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100585","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:35:26Z","timestamp":1776011726000},"page":"100585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-5290","authenticated-orcid":false,"given":"Jack T.","family":"Seki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Agustina","family":"Perusini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-8583","authenticated-orcid":false,"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lrr.2026.100585_bib0001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.lrr.2026.100585_bib0002","first-page":"5089","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years. Blood","volume":"116","author":"Kindler","year":"2010","journal-title":"J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.lrr.2026.100585_bib0003","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2026.100585_bib0004","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mole. Cancer Therapeutics"},{"issue":"8","key":"10.1016\/j.lrr.2026.100585_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2026.100585_bib0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.16092","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies","volume":"187","author":"Weisberg","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.lrr.2026.100585_bib0007","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a flt3 mutation fda approval summary: gilteritinib","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lrr.2026.100585_bib0008","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2025"},{"key":"10.1016\/j.lrr.2026.100585_bib0009","series-title":"PrXOSPATA\u00ae (gilteritinib fumarate) Tablets, 40 mg: Product Monograph Including Patient Medication Information","year":"2019"},{"issue":"7","key":"10.1016\/j.lrr.2026.100585_bib0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lrr.2026.100585_bib0011","series-title":"Midostaurin \u2013 Provider Monograph [Internet]","year":"2025"},{"key":"10.1016\/j.lrr.2026.100585_bib0012","series-title":"PrNEXAVAR\u00ae (Sorafenib Tosylate) Tablets, 200 mg: Product Monograph","year":"2014"},{"issue":"9","key":"10.1016\/j.lrr.2026.100585_bib0013","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.lrr.2026.100585_bib0014","first-page":"104","article-title":"Gilteritinib: a novel FLT3 inhibitor for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Marjoncu","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2026.100585_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2010.01059.x","article-title":"Sorafenib-associated hand\u2013foot syndrome in Japanese patients","volume":"38","author":"Iijima","year":"2011","journal-title":"J. Dermatol."},{"issue":"3","key":"10.1016\/j.lrr.2026.100585_bib0016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/0253-7613.132189","article-title":"Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma","volume":"46","author":"Sil","year":"2014","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.lrr.2026.100585_bib0017","doi-asserted-by":"crossref","unstructured":"Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui C-H, Ribeiro RC, Campana D, and Baker SD. Phase I Pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia. J. Clin. Oncol. 29:3293-3300.","DOI":"10.1200\/JCO.2011.34.7427"},{"key":"10.1016\/j.lrr.2026.100585_bib0018","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lrr.2026.100585_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand\u2013foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.lrr.2026.100585_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.lrr.2026.100585_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.lrr.2026.100585_bib0022","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2026.100585_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420986241284105","article-title":"A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Zhou","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.lrr.2026.100585_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2024.12.034","article-title":"Gilteritinib-induced pyoderma gangrenosum in a patient with acute myeloid leukemia: a case report","volume":"58","author":"Sisley","year":"2025","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.lrr.2026.100585_bib0025","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/CAD.0000000000001634","article-title":"Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report","volume":"35","author":"Rold\u00e1n","year":"2024","journal-title":"Anti-Cancer Drugs"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:10:46Z","timestamp":1785481846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"alternative-id":["S2213048926000257"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100585","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100585"}}